ClinicalTrials.gg
CompletedNCT05832879Updated Nov 19, 2026Results posted

Telehealth Treatment for Opioid Use Disorders

An interventional study of OUD Telehealth Platform in Opioid Use Disorder, sponsored by Yale University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Yale University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Opioid-Related Disorders by Yale University — 20 open to participants now, 24 under way, 1 of them phase 3. Opioid-Related Disorders · Yale University.

Enrollment
60th of 94
33 · median 62
Started
2024
with 8 others
No phase
44 of 106
7 open now
Registered
86th of 106
by date

Among the 106 studies in Opioid-Related Disorders by Yale University, this one is the 60th largest by enrollment of the 94 interventional ones that give a count, is one of 9 that started in 2024, is one of 44 with no phase, and was the 86th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

20 of the 106 studies in Opioid-Related Disorders by Yale University are open now, in 4 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Opioid-Related Disorders by Yale University, or all of them as a file.
02

Study summary

This study aims to use an Opioid Use Disorder (OUD) Telehealth Platform to reduce overdose events. This telehealth platform will be pilot tested to evaluate its preliminary efficacy in terms of motivating engagement in medications for OUD (MOUD), as well as its feasibility, acceptability and satisfaction to both first responders/providers and participants.

Read the detailed description

The primary objective of the study is to assess effects of enrollment in a comprehensive telehealth platform, in adults with moderate or severe opioid use disorder with a history of at least one opioid overdose. Adults with moderate or severe opioid use disorder with a history of at least one opioid overdose will be enrolled and the primary endpoint will be attendance at first appointment for medication for opioid use disorder at 30 days.

Secondary aims include assessing engagement in the first MOUD appointment at 90 days and self-report of the number of subsequent overdose events at 30 and 90 days. Exploratory aims include feasibility of intervention, readiness and intention to engage in treatment, acceptability and satisfaction of intervention, and comparison of MOUD engagement with data from previous in-person studies.

03

Conditions studied

  • Opioid Use Disorder

Keywords

  • Harm Reduction
  • Medication for Opioid Use Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Can speak, read and write in English
  • Provision of signed and dated form
  • Have a history of at least one opioid overdose
  • Screened positive for OUD, moderate or severe, based on the Diagnostic and Statistical Manual-5th Edition
  • Have a working cell phone number and working device that can access a web browser and receive texts (i.e., smartphone, tablet or computer) OR be willing to use a device provided by the study team
  • Can provide a working email address OR be willing to create one

Exclusion criteria

Exclusion Criteria:

  • Current use of buprenorphine, methadone, or naltrexone for a substance use disorder
  • Pregnancy
  • Known current suicide risk based on participant self-report
  • On parole or incarcerated at time of enrollment based on participant self-report
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    OUD Telehealth Platform

    Participants will be assigned to receive the OUD Telehealth Platform, which will be delivered remotely by research staff.

    Behavioral: OUD Telehealth Platform

Interventions

  • BehavioralOUD Telehealth Platform

    The platform is intended to encourage engagement in treatment with medications for opioid use disorder (MOUD) through a chat dialogue with users

06

What researchers measure

Primary outcomes

  1. Attendance for MOUD

    Overall attendance will be measured by attendance (yes or no) at the first buprenorphine appointment within 30 days of referral.

    Time frame: Up to 30 Days

Secondary outcomes

  1. Overdose Events at 30 Days

    A self-report of the number of subsequent overdose events at 30 days.

    Time frame: Up to 30 days

  2. Overdose Events at 90 Days

    A self-report of the number of subsequent overdose events at 90 days.

    Time frame: Up to 90 days

  3. Engagement With MOUD

    Engagement will be measured by demonstrated maintained attendance with MOUD treatment within 90 days of referral of those participants that engaged with MOUD. This will be collected by self-report survey as yes or no if there was continued engagement with MOUD.

    Time frame: Up to 90 days

07

Results

Posted Nov 19, 2026

Participant flow

Participant flow — Overall Study
MilestoneOUD Telehealth Platform
Started33
Completed31
Not completed2
Withdrew: Protocol violation2

Outcome measures

PrimaryAttendance for MOUD

Overall attendance will be measured by attendance (yes or no) at the first buprenorphine appointment within 30 days of referral.

Time frame:
Up to 30 Days
Reported as:
Count of participants · Participants
Attendance for MOUD
ParticipantsOUD Telehealth Platform
Yes1
No24
SecondaryOverdose Events at 30 Days

A self-report of the number of subsequent overdose events at 30 days.

Time frame:
Up to 30 days
Reported as:
Median · Number of overdose events
Overdose Events at 30 Days
Number of overdose eventsOUD Telehealth Platform
Overdose Events at 30 Days0 (0 to 3)
SecondaryOverdose Events at 90 Days

A self-report of the number of subsequent overdose events at 90 days.

Time frame:
Up to 90 days
Reported as:
Median · Number of overdose events
Overdose Events at 90 Days
Number of overdose eventsOUD Telehealth Platform
Overdose Events at 90 Days0 (0 to 2)
SecondaryEngagement With MOUD

Engagement will be measured by demonstrated maintained attendance with MOUD treatment within 90 days of referral of those participants that engaged with MOUD. This will be collected by self-report survey as yes or no if there was continued engagement with MOUD.

Time frame:
Up to 90 days
Reported as:
Count of participants · Participants

No measurements were reported for this outcome.

Adverse events

Collected over From enrollment until end of follow-up, up to 90 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OUD Telehealth Platform0/33 (0%)0/33 (0%)0/33 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(year)OUD Telehealth Platform
Mean32.1 ± 7.58
Sex: Female, Male
Sex: Female, Male(Participants)OUD Telehealth Platform
Female14
Male19
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OUD Telehealth Platform
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American25
White6
More than one race1
Unknown or Not Reported1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OUD Telehealth Platform
Hispanic or Latino0
Not Hispanic or Latino32
Unknown or Not Reported1
08

Study locations

1 site
  • Yale School of Medicine
    New Haven, Connecticut 06520, United States
09

References and documents

Publications

  • Canty T, S Sabounchi N, Heimer R, Pantalon M, Ryus C, Buchanan L, Grewal M, Maffei J, D'Onofrio G, Heckmann R. Increasing timely access to evidence-based treatment for opioid use disorder using novel digital health and system dynamics modelling approaches: a study protocol. BMJ Open. 2025 Nov 4;15(11):e102796. doi: 10.1136/bmjopen-2025-102796. PubMed 41193189 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data will be shared as part of the HEAL Initiative Consortium.

Time frame: Following the close of the study and final reporting to funder.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Jul 2025, 14 months.

Results were first posted in Nov 2026, 1 year 3 months after primary completion.

Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's 14 months is below that.

Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2023
First posted
Apr 27, 2023
StartActual
May 1, 2024
Primary completionActual
Jul 24, 2025
CompletionActual
Jul 24, 2025
Results first posted
Nov 19, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 19, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedEngagement withWith MOUDTime frame: Up to 90 days
Nov 19, 2026
Sponsor
Collaborators added: City University of New York, School of Public Health
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Results posted
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedEngagement withWith MOUDTime frame: Up to 90 days
    Sponsor Collaborators added: City University of New York, School of Public Health
    + 4 other changes: verification date, oversight details, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05832879
Lead sponsor
Yale University
Collaborators
National Institute on Drug Abuse (NIDA), City University of New York, School of Public Health
Responsible party
Sponsor
First posted
Apr 27, 2023
Start date
May 1, 2024
Primary completion
Jul 24, 2025
Completion
Jul 24, 2025
Results posted
Nov 19, 2026
Last update
Nov 19, 2026

Study contacts

Rebekah Heckmann, MD, MPH, MPA
principal investigator · Yale University
Nasim Sabounchi, PhD
principal investigator · CUNY Graduate School of Public & Health Policy

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion